| 1. |
Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome:analysis of fourteen cases with review of the literature[J]. Medicine, 1975, 54(1):1-27.
|
| 2. |
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues[M]. 4th ed. Geneva:World Health Organization, 2008:67-73.
|
| 3. |
Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome[J]. Annals of Internal Medicine, 1978, 89(2):167-172.
|
| 4. |
Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia:point-of-care diagnostic algorithm and treatment update[J]. Mayo Clin Proc, 2010, 85(2):158-164.
|
| 5. |
Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients[J]. Br J Haematol, 2008, 141(2):200-204.
|
| 6. |
Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFR and FIP1L1 genes as a therapeutic target of imanitib in idiopathic hypereosinophilic syndrome[J]. N Engl J Med, 2003, 348(13):1201-1214.
|
| 7. |
Klion AD, Robyn J, Maric l, et al. Relapse following discontinuation of imatinib mesylate therapy for FIPlLl/PDGFRA-positive chronic eosinophilic leukemia:implications for optimal dosing[J]. Blood, 2007, 110(10):3552-3556.
|
| 8. |
David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders[J]. Blood, 2007, 109(1):61-64.
|
| 9. |
Simon D, Salemi S, Yousefi S, et al. Primary resistance to imatinib in Fipl-like1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia[J]. J Allergy Clin Immunol, 2008, 121(4):1054-1056.
|
| 10. |
Malcovati, L, La Starza R, Merante S, et al. Hypereosinophilic syndrome and cyclic oscillations in blood cell counts. A clonal disorder of hematopoiesis originating in a pluripotent stem cell[J]. Haematologica, 2004, 89(4):497-499.
|
| 11. |
Needleman SW, Mane SM, Gutheil JC, et al. Hypereosinophilic syndrome with evolution to myeloproliferative disorder:temporal relationship to loss of Y chromosome and c-N-ras activation[J]. Hematol Pathol, 1990, 4(3):149-155.
|
| 12. |
Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases[J]. Ann Med Interne (Paris), 1989, 140(4):253-257.
|
| 13. |
Vincent EH, Joe CF, Zhou YW, et al. Hypereosinophilic syndrome[M]. Emedicine Hematology, 2004:131.
|
